MICA: Psoriasis Stratification to Optimise Relevant Therapy (PSORT)

Lead Research Organisation: University of Manchester
Department Name: School of Biological Sciences

Abstract

Psoriasis is a common, chronic, potentially disfiguring disease that affects more than 1 million people in the UK. It can cause considerable psychological and social disability. In the past 10 years there has been a dramatic improvement in clinical outcomes for patients with severe psoriasis due to the introduction of a new class of injectable drugs called biologics. These work by targeting specific parts of the immune system which are important in causing psoriasis. However, these drugs are very expensive (estimated annual cost is £10,000) and it remains the case that a significant number of patients fail to respond adequately. If we could predict which patients will do well with a particular biologic drug then we could devise new treatment plans that would be personalised for each patient rather than the current system of "trial and error" prescribing. This would be of added benefit to society as a whole since it could result in significant cost savings to the NHS and aid the pharmaceutical industry in development of new drugs.
The programme of research in the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium aims to use existing knowledge about psoriasis, both clinical and scientific, our unparalleled patient base coupled to involvement of patient organisations and state-of -the-art investigative tools to develop tests that we can use in the clinic to help direct personalised treatments. Specific questions we will ask are: i) do levels of a drug in the blood and a patient's immune response to that drug effect outcome; ii) are there specific changes in the skin and blood that predict which drug is likely to be more useful in a particular patient; iii) is there variation in a patient's genetic make-up, linked to psoriasis and how drugs work, that may predict response to treatment; and iv) does bringing all the information collected in i-iii above, though computer based data analysis, have more power to predict response to treatment?
Succssfully achieving such a goal requires a number of important criteria to be met. Perhaps most importantly we need consent from large numbers of patients to enter studies and provide samples of blood and skin. From the start of the study, we have engaged with the Psoriasis Association (patient organisation) to ensure the study met with their approval. As a consequence of patient engagement, in the UK we have arguably the world's leading safety registry for patients receiving biologic drugs for psoriasis. During the lifetime of our proposal, it will have accumulated comprehensive information on 7,000 patients including responses (good and bad) to biologics. The PSORT consortium includes representatives from 4 of the largest psoriasis clinics in the UK. These will provide the source for patient recruitment.
The experiments will take advantage of several factors. First, in contrast to many other chronic diseases, change in psoriasis severity is simple and accurate to determine after starting therapy. Second, target organ tissue (i.e. skin) can be sampled in a minimally invasive way by skin biopsy (patient feedback tells us that this is acceptable to them). Third, internationally competitive expertise exists across the consortium between investigators and collaborators in all of the scientific disciplines required to successfully deliver the programme. Fourth, appropriate research infrastructure exist at each of the three main centres namely Manchester, Newcastle and London. This includes the registry itself (Manchester) and NHS funded facilities (Newcastle and London). Finally, we have developed an extensive network of pharmaceutical company partners who bring specific expertise and resources to the programme. Not only will this help in achieving the short term goals but it will also provide the necessary platform for translating the outcomes into clinically useful tests.

Technical Summary

Biologic therapies for severe psoriasis are currently prescribed in a stochastic manner that is neither efficient nor cost-effective. The vision of the PSORT consortium is to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. To deliver this vision PSORT has brought together a powerful grouping of world-leading psoriasis researchers, bioinformaticians, statisticians, health economists and industry partners. Patient representation informs the consortium which utilises NIHR and MRC funded platforms and an established, high-quality clinical bioresource the British Association of Dermatologists' Biologic Interventions Registry (BADBIR) involving 143 UK dermatology centres (5500 patients by 2014). Two parallel, interlinked Work Strands will provide clinical, adherence, pharmacological, genetic, transcriptomic, and immune data in blood and skin on psoriasis patients treated with biologics. Deeply-phenotyped Discovery and Refinement cohorts sponsored by academia and industry are complemented by large scale validation in BADBIR and in a prospective clinical pilot study of minimal effective dosing of biologics. The data will be integrated and interrogated through TranSMART infrastructure enabling a combination of bioinformatics, machine learning and biostatistics for the discovery of drug response endotypes/biomarkers. Working with our partner diagnostics companies these will be scalable for clinical use. Operational management will be proactive and milestone driven with oversight provided by an Independent Advisory Board. It is anticipated that the PSORT consortium will be a major catalyst to deliver novel personalised medicine approaches in the management of psoriasis.

Planned Impact

The main beneficiaries of the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium will be people with psoriasis, who will have improved access to effective treatment. The majority of people who develop psoriasis are young - 75% develop the condition before 35 years of age. Thus, this predominantly lifelong condition can have a significant detriment on an individual's chances of achieving their full potential. For instance, loss of sleep and time away from school for healthcare visits and hospital admission, difficulty in forming relationships and exclusion from social and sporting activities because of the stigma of psoriasis and exclusion from public-facing employment. The wider patient impact is also important in that family members are frequently involved with the care of psoriasis patients. These all contribute to a significant burden from a disease that affects at least one million people in the UK. Optimised treatment results in improvements in quality of life, and also has the potential to impact on important associated co-morbidities such as depression, psychosocial and physical disability and cardiovascular disease.

The outputs from PSORT will allow more accurate matching of the treatment to the disease, facilitating more rapid and individualised transitioning onto the most effective and safest drug. Those who fail to respond to the initial treatment will be recognised more quickly allowing them to progress to more suitable treatment, with less exposure to ineffective treatment. Currently, patients whose disease is completely suppressed by biologic treatment continue this treatment indefinitely. PSORT will allow tailoring of drug dose to the minimum that is effective and in some, whose disease is in remission, treatment may be interrupted or stopped, reducing the risk of side-effects. It is likely that issues related to pharmacokinetics and drug immunogenicity and their association with the mechanisms of treatment failure will relate equally to patients with other immune mediated inflammatory diseases such as rheumatoid arthritis and Crohn's disease, allowing these impacts to benefit an even greater number of patients.

The pharmaceutical and biotechnology industries involved with the development of small molecules, biologics and biosimilars for psoriasis treatment will benefit from stratification, both in the identification of new therapeutic targets and in clinical trial design. These benefits will include: de-risking of drugs (for instance in dose optimisation); and using the PSORT classification of psoriasis to design adaptive trials to test new drugs in small, well-characterised cohorts of patients, including through the NIHR Translational Research Partnerships. Diagnostic companies will be able to use potential psoriasis stratifiers to develop and commercialise companion diagnostics.

Professional bodies (e.g. British Association of Dermatologists) and National Institutions (e.g. NICE and Scottish Intercollegiate Guidelines Network) responsible for the development of clinical practice guidelines will benefit from stratification of psoriasis in that patient pathways and guidance for starting and /or switching biologics will gain a substantial evidence base. In terms of education of clinical professionals, classification of psoriasis will inform future teaching and learning.

The NHS and other healthcare providers and their funders will benefit from an effective and efficient use of expensive drugs by an approach that targets those patients who are at highest likelihood of responding, informing evidence-based policy making. Dose minimisation strategies and drug discontinuation in patients who have achieved remission has the potential to make significant cost savings whilst maintaining patient benefit. Early, targeted disease altering management will benefit not only the health of individual patients but would significantly increase their contribution to society.

Publications

10 25 50

publication icon
Dand N (2019) HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. in The Journal of allergy and clinical immunology

publication icon
Foulkes AC (2017) Research Techniques Made Simple: Bioinformatics for Genome-Scale Biology. in The Journal of investigative dermatology

 
Guideline Title British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 (in press)
Description Therapeutic drug monitoring now integrated into clinical practice
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
Impact We have made personalised medicine a reality through the monitoring of therapeutic drug levels, which is now part of standard practice and has been integrated into clinical guidelines: doctors can use the genetic and biological blueprint of each patient to identify which treatments are most likely to work (and be the safest or least likely to cause side effects).
 
Description British Association of Dermatologists (BAD) conference travel bursary of £250 to R Andres-Ejarque (Kings College London) to attend BSID meeting, competitive process
Amount £250 (GBP)
Organisation British Association of Dermatologists (BAD) 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2018 
End 03/2018
 
Description Capital Investment in Human Tissue Biobanking and Linkes Data in partnership with Charities (IMID-Bio UK)
Amount £1,707,539 (GBP)
Funding ID MR/R014191/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2017 
End 03/2021
 
Description Clinical, genetic and immune determinants of drug immunogenicity in psoriasis
Amount £235,114 (GBP)
Funding ID MR/R001839/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2017 
End 10/2020
 
Description European Society for Dermatological Research (ESDR) travel grant awarded to N Dand (Kings College London) to attend ESDR meeting 2016, competitive process
Amount € 500 (EUR)
Organisation European Society of Dermatological Research (ESDR) 
Sector Charity/Non Profit
Country Switzerland
Start 09/2016 
End 09/2016
 
Description European Society for Dermatological Research (ESDR) travel grant awarded to N Dand (Kings College London) to attend ESDR meeting 2017, competitive process
Amount € 1,000 (EUR)
Organisation European Society for Dermatological Research 
Sector Learned Society
Country Switzerland
Start 09/2017 
End 09/2017
 
Description European Society for Dermatological Research (ESDR) travel grants of 1,500 each awarded to R Andres-Ejarque; T Tsakok & N Dand (Kings College) to attend IID conference, competitive process
Amount € 4,500 (EUR)
Organisation European Society of Dermatological Research (ESDR) 
Sector Charity/Non Profit
Country Switzerland
Start 05/2018 
End 05/2018
 
Description Genetics Society Juniour Scientist travel grant awarded to N Dand (Kings College London) to attend 2017 GRC Quantitative genetics meeting
Amount £750 (GBP)
Organisation The Genetics Society 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2017 
End 03/2017
 
Description Identifying immune determinants of clinical response to ustekinumab in psoriasis
Amount £85,500 (GBP)
Funding ID ST1/19 
Organisation The Psoriasis Association 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2019 
End 10/2022
 
Description Investigating genetic control of the psoriasis transcriptome to define and validate drug and disease endotypes
Amount £85,500 (GBP)
Funding ID ST1/18 
Organisation The Psoriasis Association 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2018 
End 10/2021
 
Description MRC Stratified Medicine Consortium Awards
Amount £4,900,000 (GBP)
Funding ID MR/L011808/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2014 
End 08/2018
 
Description Psoriasis: From Gene to Clinic Congress Education Grant awarded to N Dand (Kings College London) for registration for Psorisis: from gene to clinic meeting
Amount £300 (GBP)
Organisation National Center for Biotechnology Information (NCBI) 
Sector Public
Country United States
Start 11/2017 
End 12/2017
 
Title PSORT-D blood RNASeq data 
Description We recently received blood RNASeq data for the PSORT Discovery cohort from our industrial partners at Abbvie. This will facilitate transcriptomic analysis of skin and blood in parallel, and the identification of concordant and discordant biological themes in both datasets. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? No  
Impact In development 
 
Description PSORT 
Organisation AbbVie Inc
Country United States 
Sector Private 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation Becton, Dickinson and Company
Country United States 
Sector Private 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation British Association of Dermatologists (BAD)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation Celgene
Country United States 
Sector Private 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation Eli Lilly & Company Ltd
Country United Kingdom 
Sector Private 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation GlaxoSmithKline (GSK)
Department Steifel
Country United States 
Sector Private 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation Guy's and St Thomas' NHS Foundation Trust
Department Dermatology
Country United Kingdom 
Sector Hospitals 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation Johnson & Johnson
Department Janssen-Cilag
Country Global 
Sector Private 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation LEO Pharma
Country Ireland 
Sector Private 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation MedImmune
Country United States 
Sector Private 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation NHS Greater Glasgow and Clyde (NHSGGC)
Country United Kingdom 
Sector Public 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation Newcastle University
Department Dermatological Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation Pfizer Ltd
Country United Kingdom 
Sector Private 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation Qiagen
Country Netherlands 
Sector Private 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation Queen Mary University of London
Country United Kingdom 
Sector Academic/University 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation Royal College of Physicians of London
Country United Kingdom 
Sector Learned Society 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation Royal College of Physicians of London
Country United Kingdom 
Sector Learned Society 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation Sanquin
Country Netherlands 
Sector Private 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation The Psoriasis Association
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description PSORT 
Organisation University of Liverpool
Country United Kingdom 
Sector Academic/University 
PI Contribution The team have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings.
Collaborator Contribution The partners have worked to build a consortium to secure MRC and industry funding to develop a stratified medicine approach for psoriasis to better understand determinants of response to biologic therapies and deliver, in close collaboration with commercial partners, a PSORT stratifier (algorithm) to guide psoriasis management. This will optimise clinical pathways for psoriasis, inform the management of other less accessible immune-mediated inflammatory diseases and deliver health care savings. Partners are contributing clinical, biostatistical, bioinformatics, skin biology, nursing, clinical dermatology, machine learning, health economics, pharmacy, genetics, systems biology and management and governance expertise. As well as equipment, software, clinical trial samples, somalogic testing, RNA extraction and sequencing, methodological know-how, clinical trial datasets, data management and pharmacovigilance data. Industry partners are contributing in excess of £2.5million of combined monetary and in-kind contributions.
Impact Received funding award of £4.9 million from the MRC Stratified Medicine Consortium programme and a further contribution of >.£2.5 million investment (both in-kind and monetary) from industry partners PSORT is a multi-disciplinary consortium involving: clinical dermatology skin biology nursing bioinformatics biostatistics machine learning health economics pharmacy genetics systems biology management and governance
Start Year 2014
 
Description Psoriasis biologics PKPD 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Joint supervised study conception, analysis and manuscript preparation. Provided data. Analysis.
Collaborator Contribution Joint supervised study conception, analysis and manuscript preparation.
Impact Published manuscript PubMed ID 31995663
Start Year 2018
 
Title Psoriasis Shout Out 
Description The Psoriasis Shout Out is a unique patient and public engagement initiative founded at Manchester University. The brand and name is registered for protection so it can be licensed for use when the initiative was expanded and rolled out to the universities of King's College London, Newcastle and Dublin. 
IP Reference  
Protection Trade Mark
Year Protection Granted 2015
Licensed Yes
Impact The Psoriasis Shout Out now has an international reputation and has been transformational for patients by educating them on the latest medical treatments for the disease, methods and techniques for self management and understanding that there is hope - patients can live well with the disease with the right professional health care and with self-management.
 
Description "A glimpse of the future: addressing the burden of moderate disease", 28th European Academy of Dermatology and Venereology (EADV) Congress - The Modern Face of Dermatology, Madrid, Spain, 9-14 October 2019. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A talk delivered as part of the 28th European Academy of Dermatology and Venereology (EADV) Congress - The Modern Face of Dermatology - with a reach of over 12000 attendees.
Year(s) Of Engagement Activity 2019
URL https://eadvmadrid2019.org/wp-content/uploads/2019/09/9517-EADV-Final-Programme-Madrid-2019-web2.pdf
 
Description "Attracting and selecting high impact clinical trials", British Journal of Dermatology (BJD) Team Editorial Team Training Day, Liverpool, 1 July 2019. 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Team Editorial Training Day: Objective - discussions focussed on attracting and selecting high impact dermatology related clinical trials
Year(s) Of Engagement Activity 2019
 
Description "Biologics for psoriasis", Manchester Preceptorship Event, Chancellors Hotel, 27 September 2019 and Whitworth Art Gallery, Manchester, 12-13 December 2019 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Manchester Preceptorship - two locally run events to support new dermatology practitioners
Year(s) Of Engagement Activity 2019
 
Description "Biologics in psoriasis as first line therapy in moderate psoriasis - no", 28th European Academy of Dermatology and Venereology (EADV) Congress - The Modern Face of Dermatology, Madrid, Spain, 9-14 October 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Talk delivered as part of the EADV's 28th Annual meeting more specifically, as part of its controversies forum on the area of Biologics in skin diseases.
The talk entitled "Biologics in psoriasis as first line therapy in moderate psoriasis - no" was delivered to a mixed audience.
Year(s) Of Engagement Activity 2019
URL https://eadvmadrid2019.org/
 
Description "Biologics", International Psoriasis Council (IPC) Psoriasis Master Class, Cairo, Egypt, 4-5 April 2019. 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The IPC Psoriasis Master Class in Cairo is designed for dermatologists who are making treatment decisions and caring for patients with psoriasis in Egypt. The program provides a comprehensive approach to psoriasis management and equip attendees with the latest and most cutting-edge information available.

Over the two days of the course, IPC's world-renowned experts cover a variety of topics including the pathogenesis of psoriasis, new and emerging therapies and how to be an advocate for your patient.

The Master Class agenda has been developed to provide knowledge for daily use to the practicing dermatologist in an intimate environment designed to maximize faculty/participant interactions. Through lectures, panels, case-based discussions and question-answer sessions, attendees can obtain practical and important information for their dermatology practice. Source: IPC Website
Year(s) Of Engagement Activity 2019
URL https://www.psoriasiscouncil.org/masterclass_cairo.htm
 
Description "Clinical/academic expert perspective", Future of Immunology Parlimentary Roundtable meeting, House of Commons, London, 4 March 2020. 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact A clinical/academic expert perspective on the future of Immunology Parliamentary Roundtable meeting at the house of House of Commons
Year(s) Of Engagement Activity 2020
 
Description "Global Psoriasis Atlas and research opportunities", British Association of Dermatologists (BAD) Dermatology Global Health Day, London, 3 October 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A talk pertaining to research opportunities with the Global Psoriasis Atlas, a collaboration between three leading international organisations in world dermatology: International Federation of Psoriasis Associations (IFPA); International League of Dermatological Societies (ILDS); and International Psoriasis Council (IPC).

The GPA aims to inform on the worldwide epidemiology of psoriasis. Its authoritative resource on psoriasis was first published in 2019.

The GPA will be updated annually, in global collaboration with their dermatologists and international organisations around the world. (See GPA website - https://globalpsoriasisatlas.org/about)

As part of the Dermatology Global Health Day in London, this talk was aimed at disseminating information pertaining to the GPA research opportunities to a mixed audience and aimed in part to achieve further involvement.
Year(s) Of Engagement Activity 2019
 
Description "Heterogeneity and Outcome Prediction in Psoriasis", National Psoriasis Foundation (NPF) Cure Symposium, Seattle, 31 May 2019. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Symposium Goal - The 2019 NPF Future of Psoriatic Disease Symposium will inaugurate a new NPF effort to develop a scientific roadmap to achieve prevention, precision medicine, and a cure for psoriatic diseases. Psoriatic disease is a heterogeneous immune-mediated disease affecting the skin, the joints, and other organ systems. The meeting was intended to provide a venue for education, dissemination of scientific results, and collaboration between clinicians and scientists to advance new discoveries. See NPF Website
Year(s) Of Engagement Activity 2019
URL https://www.psoriasis.org/cure-symposium/agenda
 
Description "How P4 medicine will transform dermatological care", 49th Annual European Society for Dermatological Research (ESDR) Meeting, Bordeaux, France, 18-21 September 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The ESDR facilitates and drives initiatives to encourage high quality science, discussion, education and mentoring for future leaders in skin science. The 2019 meeting program built on the successes of previous meetings and included changes to the program to further enhance scientific discussion and opportunities for both scientists and clinicians to present their data. This talk was given to a mixed audience and focussed specifically on how precision medicine could help to transform dermatological care.
Year(s) Of Engagement Activity 2019
URL http://esdrmeeting.org/index.php/esdr-previous-meetings/
 
Description "Myanmar and Burma Skincare Initiative-partnering with centres overseas", British Association of Dermatologists (BAD) Dermatology Global Health Day, London, 3 October 2019. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact A talk focussed on the Myanmar and Burma Skincare Initiative-partnering with centres overseas and associated efforts to ensure dermatology care to disadvantaged communities.
Year(s) Of Engagement Activity 2019
 
Description "Next Generation Healthcare and the management of psoriasis", 19th Edition Dubai Derma Congress, Dubai, 18-20 March 2019. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact "Dubai Derma is the pioneer and largest event in the Middle East, Africa and Indian Subcontinent region dedicated to dermatology, skin care and lasers.

Dubai Derma provides the best platform for all participants to boost and update their knowledge in dermatological science and technology through a variety of courses, workshops and lectures. Additionally, the scientific program provides an ideal setting for specialists and practitioners in this field to strengthen existing collaborations and develop new ones with their counterparts from all over the world.

In addition to the excellent educational opportunities, a specialised exhibition held in conjunction with the conference, provides an avenue for business entities in the industry to showcase and promote the most up-to-date equipment." Ref: https://dubaiderma.com/about-derma/
Year(s) Of Engagement Activity 2019
URL https://dubaiderma.com/about-derma/
 
Description "Optimising biologic treatment for psoriasis-which comes first?", Slovenian Dermatology Association meeting, Portorož, 18-19 October 2019. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The Slovenian Dermatology Association Meeting 2019 is an event delivered to dermatologists in order to highlight and share clinical experience and advancements in the field with the aim of improving patient care and furthering collaborative efforts to do so.
Year(s) Of Engagement Activity 2019
 
Description "Personalized psoriasis management", International Psoriasis Council (IPC) Psoriasis Master Class, Cairo, Egypt, 4-5 April 2019 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The IPC Psoriasis Master Class in Cairo is designed for dermatologists who are making treatment decisions and caring for patients with psoriasis in Egypt. The program provides a comprehensive approach to psoriasis management and equip attendees with the latest and most cutting-edge information available. Over the two days of the course, IPC's world-renowned experts cover a variety of topics including the pathogenesis of psoriasis, new and emerging therapies and how to be an advocate for your patient. The Master Class agenda has been developed to provide knowledge for daily use to the practicing dermatologist in an intimate environment designed to maximize faculty/participant interactions. Through lectures, panels, case-based discussions and question-answer sessions, attendees can obtain practical and important information for their dermatology practice. Source: IPC Website
Year(s) Of Engagement Activity 2019
URL https://www.psoriasiscouncil.org/masterclass_cairo.htm
 
Description "Photoageing in the 21st Century", 2019 Ian Magnus Memorial Lecture, European Society of Photodermatology (ESPD), 28th European Academy of Dermatology and Venereology (EADV) Congress-The Modern Face of Dermatology, Madrid, Spain, 9-14 October 2019. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The ESPD's objectives include the promotion of interaction between clinicians and scientists of all, but particularly European nationalities; the provision of advice to the general public on the adverse effects of excessive sunlight and sunbed exposure; the development of guidelines for therapeutic and diagnostic photodermatological procedures; the encouragement of organised scientific research, and the fostering of photodermatological education through the organisation of regular scientific meetings and symposia.

The focus of the ESPD's 2019 Ian Magnus Memorial Lecture was a talk by Prof Chris Griffiths on Photoageing in the 21st Century.
Year(s) Of Engagement Activity 2019
URL http://www.espd.eu.com/doc/201910-ESPDProgramme_Madrid.pdf
 
Description "Psoriasis lessons: History, science and geography", National Congress of Dermatology, Thessaloniki, Greece, 31 October to 3rd November 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A talk regarding psoriasis research from a historic, scientific and geographical perspective delivered as part of the Greek National Congress of Dermatology with the aim of providing more comprehensive information to the Dermatology community on new scientific achievements and developments .
Year(s) Of Engagement Activity 2019
 
Description "Psoriasis: Navigating the psoriasis treatment armamentarium", Euroderm Excellence Event, A.Roma Lifestyle Hotel, Rome, 21 November 2019. 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This activity is the 16th edition of the Euroderm Excellence course of the European Dermatology Forum for residents in DermatoVenereology. Organised by the EDF, the course was offered to the best residents in Dermatology and Venereology throughout Europe. The theme for Euroderm Excellence 2019 was: "Preparing a bright future for Dermatology". 230 candidates applied for entry and 100 residents selected to participate with the intention to foster young gifted Dermatologists in Europe.
Year(s) Of Engagement Activity 2019
URL https://www.edf.one/home/News/Newsletter/EDF-Newsletter-Sep.2019/NL_EE2019.html
 
Description "Stratifying outcomes in Psoriasis: a multi-omic approach", 44th Annual Meeting of the Japanese Society for Investigative Dermatology, Aomori, Japan, 8-11 November 2019. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The theme for the 44th Annual Meeting of The Japanese Society for Investigative Dermatology was 'Dermatological researches in a new era "REIWA".' This event allowed for the discussion and dissemination of scientific and clinical challenges and advances in dermatology to a wide range of audiences.
Year(s) Of Engagement Activity 2019
URL https://jsid44.jp/En/greet.html
 
Description "The skin-brain axis in inflammatory skin disease", 28th European Academy of Dermatology and Venereology (EADV) Congress - The Modern Face of Dermatology, Madrid, Spain, 9-14 October 2019. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The annual EADV Conference hosts a number of sessions of different formats covering the important fields of dermatology and venereology. This activity was run as part of the EADV President's Symposium captioned "Skin and brain: Unraveled connections" and allowed for discussion of advancements and challenges in relation to various important fields of study that might lead to improved management of inflammatory skin disease.
Year(s) Of Engagement Activity 2019
URL https://eadvmadrid2019.org/scientific/president-symposium/
 
Description 2018 Psoriasis Shout Out (Newcastle) - Let's talk about psoriasis: Q&A session with Prof Nick Reynolds 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact Q&A session about living with and managing psoriasis delivered by Prof Nick Reynolds, Professor of Dermatology at Newcastle University and a Honorary Consultant Dermatologist at Newcastle upon Tyne Hospitals NHS Foundation Trust. Interactive session to raise awareness, share information and answer questions regarding psoriasis and its management.
Year(s) Of Engagement Activity 2018
 
Description 2018 Psoriasis Shout Out (Newcastle) - Rolling short films about living with psoriasis 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact Rolling short films about living with psoriasis - an awareness raising event about people's experiences of living with and managing the condition.
Year(s) Of Engagement Activity 2018
 
Description 2018 Psoriasis Shout Out Week - Manchester (Lead), London, Dublin, Newcastle 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Started by scientists from the Manchester Centre for Dermatology Research, the aim of the Psoriasis Shout Out is to spread the word about what psoriasis is and what it isn't, and to bring psoriasis patients together with professionals working in the field to bring about more progressive research.

The profile-raising initiative has taken many different forms in the years since it started, using activities to start meaningful conversation and sharing. Staff and visitors at the University of Manchester and partner hospitals had the opportunity to try mindfulness and yoga techniques to help reduce the stress and anxiety that can be a side effect of the condition, whilst the roadshows took the message to the members of the public in Dublin, Newcastle and London.

In 2018, to mark the 50th anniversary of the UK Psoriasis Association, many people created 50 second video shout-outs, posted on YouTube. Mostly from scientists in the field, the videos capture thoughts about psoriasis and psoriasis research, set out aims of current work or feedback on recently published work to demonstrate the importance of this research.

This digital campaign follows on from their wonderful 'Flashmob' video' for the 2016 Shout Out, which stared patients groups, healthcare professionals 'Psoriasis Shout Out juniors', and Professor Chris Griffiths, who leads the initiative.

The effects of the condition are more than skin-deep and can have a significant impact upon an individual's quality of life, but the overarching message from Psoriasis Shout Out is a positive one: it is perfectly possible to live well with psoriasis and more people need to know that.
(Credit: Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Newsletter 6 Feb 2019.
Year(s) Of Engagement Activity 2016,2018
URL https://www.psoriasisshoutout.co.uk/
 
Description 28th EADV Congress - Madrid 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Chair and Speaker for EADV Review and Updates session "Immunopathogenesis, lessons learned from psoriasis"
Year(s) Of Engagement Activity 2019
 
Description 300th meeting of Department of Dermatology and Allergy, Gentofte Hospital, University of Copenhagen 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact The Department of Dermatology and Allergy, Gentofte Hospital, University of Copenhagen organise one meeting each semester which involve patient demonstrations followed by an invited speaker and a few local talks. The audience is mainly dermatologists in private practice and young dermatologists. The talk lasted for 30 minutes followed by 10 minutes for discussion. The purpose was to provide young dermatologists with new knowledge and clinical data.
Year(s) Of Engagement Activity 2019
 
Description 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN 2019) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Speaker for the Plenary Session 1 "Plenary Session 1: Genetics and Pathogenesis in Psoriasis and Atopic Dermatitis", to hold a lecture on the topic "Genetics in psoriasis and atopic dermatitis".
Year(s) Of Engagement Activity 2019
 
Description 6th annual "A Day @ St John's" course 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact informal talk for 20 mins (+ 10 mins for Q&A) on "Inflammatory Dermatoses" aimed at junior doctors and medical students across the country who are keen to pursue a career in dermatology.
Year(s) Of Engagement Activity 2019
 
Description A national public engagement event 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact The Psoriasis ShoutOut 2016 extended the original 2014 Manchester Psoriasis Shoutout to involved partners from several sites around the country, the Republic of Ireland as well as others in the US and Singapore.
Year(s) Of Engagement Activity 2014,2016
URL http://www.psoriasisshoutout.co.uk/
 
Description ANNUAL UK DERMATOLOGY COURSE FOR CONSULTANTS 2019 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The Annual UK Consultants Course is aimed at UK based Consultant Dermatologists in active dermatological practice (who are on the Specialist Register).
Year(s) Of Engagement Activity 2019
 
Description Advanced Medical Dermatology Therapeutics Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact "How do newly approved drugs for psoriasis really stack up against older biologics and old favourites?" - chairing the psoriasis session "New therapies vs old "
Year(s) Of Engagement Activity 2019
 
Description Advanced Medical Dermatology Therapeutics Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact A two-day meeting with a mixture of plenary talks and case presentations. The audience will be about 80% Consultant Dermatologists from the UK (approx. 150 -200 persons).
The meeting will cover a range of dermatological conditions. The focus of the meeting will be on the therapy of the conditions with an emphasis on the complex case.

The range of topics covered will bring the attendee up to date with the latest evidence for management of complex medical dermatology and practical guidance on advanced prescribing.
Year(s) Of Engagement Activity 2019
 
Description Biology of the Skin 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Invitation to speak at annual Introduction to the Biology of the Skin course
Year(s) Of Engagement Activity 2019
 
Description EADV 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact International Psoriasis Council Symposium "Hot topics and challenging cases in psoriasis": facilitiating multiple sessions
Year(s) Of Engagement Activity 2019
 
Description Essential Medical Dermatology Course 2020 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Essential Medical Dermatology is a 3 day course organised by the British Society for Medical Dermatology, aimed at dermatology StRs & Consultants (although Speciality doctors and Associate Specialists are also eligible to attend) who wish to refresh their knowledge of medical dermatology. Expecting 60 delegates to be in attendance. Talk on "How I approach difficult psoriasis"
Year(s) Of Engagement Activity 2020
 
Description European Dermatology Forum Annual Meeting 2020 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Chairing session at European Dermatology Forum Annual Meeting 2020
Year(s) Of Engagement Activity 2020
 
Description GRAPPA Annual Meeting and Trainee Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Lecture entitled "Towards precision medicine in psoriasis: update from BADBIR and PSORT programs
Year(s) Of Engagement Activity 2019
 
Description Genomics for Dermatology (Prof Catherine Smith) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Prof Catherine Smith (King's College London) gave a talk entitled: 'Genetic mechanisms applied to therapy developments in psoriasis and eczema'.

Impact - Generation of further interest in the outcomes of PSORT and contribution to the wider field.
Year(s) Of Engagement Activity Pre-2006,2006,2018
 
Description How Precision Medicine will transform Healthcare 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact Audience: Staff and students engaged in or supporting all P4 medicine research affiliated with the BRC, The University of Manchester and/or Health Innovation Manchester.

This event was designed to provide all staff and students with the opportunity to update their knowledge and skills on P4 Medicine (Predictive, Preventive, Personalised and Participatory)

This event, in partnership with Manchester Precision Medicine Institute (MPMI) and Health Innovation Manchester, aimed to provide attendees with an understanding of implementation of precision medicine approaches and an overview of some of the existing research in this area across Manchester including PSORT and within industry.
Year(s) Of Engagement Activity 2018
 
Description IPC Satellite Symposium at 24th World Congress of Dermatology (WCD) in Italy 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This was an IPC sympsium for members of the IPC to participate in a programme titled "Hot topics and challenging cases in psoriasis: A focus on pustular, biosimilars, pediatrics and treating in under-served areas". A brief discussion took place with each speaker after their lecture and the audience participated in Q&A after the lectures. The second part of the symposium involved challenging cases presented by the faculty and another opportunity for the audience to ask questions. The event was well received and there was an increased interest in related subject areas.
Year(s) Of Engagement Activity 2019
URL https://www.psoriasiscouncil.org/agenda_wcd2019.htm
 
Description Internation Psoriasis Council 2019 Think Tank 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Gave lecture on "Therapeutic drug monitoring and personalized dosing of biologics"
Year(s) Of Engagement Activity 2019
 
Description Invited Speaker - LEO Foundation Skin Immunology Center Inauguration, Copenhagen, 25 February 2019 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The LEO Foundation Skin Immunology Research Center at the University of Copenhagen was officially opened on Monday 25 February 2019 and inaugurated by His Royal Highness Prince Joachim and Tommy Ahlers, Minister for Higher Education and Science. Over the next 10 years, the research center will conduct top-level international research into the skin's immune system and its diseases.

As reported by Jesper Mailind, CEO, LEO Foundation, by combining research into skin and the immune system, the LEO Foundation hopes to support world class research at the University of Copenhagen. The aim of the new center is to increase their understanding of skin conditions and enable them to find better ways of treating and completely curing them in the future.
Year(s) Of Engagement Activity 2019
URL https://leo-foundation.org/en/2019/02/21/grand-opening-of-the-leo-foundation-skin-immunology-researc...
 
Description Invited seminar: Transcriptomic analysis of psoriasis (Prof Nick Reynolds) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Professor Nick Reynolds (Newcastle University - PSORT Consortium Partner) co-led and gave a seminar on research techniques course for UK trainees in dermatology in Newcastle that received excellent feedback.
Year(s) Of Engagement Activity 2018
 
Description Japanese Society for Investigative Dermatology Meeting (JSID) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Chair and speaker for IPC symposium
Year(s) Of Engagement Activity 2019
 
Description Lecture - "Can we prevent ageing?",19th Edition Dubai Derma Congress, Dubai, 18-20 March 2019. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact "Dubai Derma is the pioneer and largest event in the Middle East, Africa and Indian Subcontinent region dedicated to dermatology, skin care and lasers.

Dubai Derma provides the best platform for all participants to boost and update their knowledge in dermatological science and technology through a variety of courses, workshops and lectures. Additionally, the scientific program provides an ideal setting for specialists and practitioners in this field to strengthen existing collaborations and develop new ones with their counterparts from all over the world.

In addition to the excellent educational opportunities, a specialised exhibition held in conjunction with the conference, provides an avenue for business entities in the industry to showcase and promote the most up-to-date equipment." See https://dubaiderma.com/about-derma/
Year(s) Of Engagement Activity 2019
URL https://dubaiderma.com/about-derma/
 
Description Lecture - What's the Future? Dermatology Innovation Forum, 2019 American Academy of Dermatology Meeting (AAD), Washington DC, 28 February 2019. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact "The mission of the Dermatology Innovation Forum is to build a community of dermatologists and their colleagues who are excited about developing ideas into products which can substantially improve skin health.

Held in association with the American Academy of Dermatology annual meeting, the forum focuses on educating participants about inspiring innovations that can provide a basis for the generation of important dermatology products and services. By including physicians, researchers, inventors, investors, strategic corporate partners, service providers, government regulators, patient advocates, and other stakeholders, the Forum also provides a unique networking venue for its attendees to communicate with, learn from, and collaborate with each other." Ref: Dermatology Forum Website
Year(s) Of Engagement Activity 2019
URL http://www.dermsummit.com/2019/dif/
 
Description Lecture on Psoriasis - Department of Dermatology, University of Würzburg, Germany 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Invitation to give a talk on "The evolution of systemic therapy for psoriasis" to students
Year(s) Of Engagement Activity 2019
 
Description New Zealand Dermatological Society Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A scientific conference only open to fully qualified dermatologists and trainees which takes place annually. The programme consists of dermatologist speakers which sparked questions and discussion afterwards. Feedback indicated an increased interest in subject.
Year(s) Of Engagement Activity 2019
URL https://www.nzdsi.org/News/View.aspx?articleid=83848f2e-4c76-4f02-9810-152b19ad5152
 
Description PSORIASIS WORKSHOP for medical students 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact Talk on "Treatment options in psoriasis (including biologicals)"
Year(s) Of Engagement Activity 2020
 
Description PSORT Consortium Dissemination Showcase November 2019 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium Showcase was held on 18th November 2019 at the Royal College of Physicians in London to highlight the progress, achievements and potential clinical impact of the ongoing PSORT stratified medicine programme. The event was delivered to a mixed audience including patients/patient groups, main funder the Medical Research Council, industry, other consortia, ABPI, NIHR, clinicians, academics and local government.

The event was a great success and has resulted in the planning of future related activity pertaining to psoriasis research and other immune mediated inflammatory diseases.
Year(s) Of Engagement Activity 2019
 
Description PSORT Consortium Showcase 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Gave talk "Genetic determinants of therapeutic response"
Year(s) Of Engagement Activity 2019
 
Description PSORT Consortium Showcase 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Gave talk "Drug exposure, anti-drug antibodies and treatment response"
Year(s) Of Engagement Activity 2019
 
Description PSORT Research Users Groups 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Meetings of patients / research users have been held at three PSORT centres. the meetings are to keep patients informed and to seek advice from patients regarding the ongoing development of the research programme.
Year(s) Of Engagement Activity 2014,2015
 
Description Pleanry Talk, 24th World Congress of Dermatology (WCD) in Italy 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Plenary talk discussing psoriasis which took place at The World Congress of Dermatology, one of the most widely recognised international dermatology meetings.
The plenary session involved six speakers which sparked questions and discussion afterwards. Feedback indicated an increased interest in subject.
Year(s) Of Engagement Activity 2019
URL https://www.wcd2019milan.org/wcd2019/
 
Description Preceptorship for Lilly 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Talk on "Treatment approaches". 22 people attending from Lilly: 7 physicians, 4 medical and 11 marketeers, the majority interested in hearing about clinician's perspectives of disease and real world experience.
Year(s) Of Engagement Activity 2020
 
Description Psoriasis Association 50th Anniversary Annual Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The annual conference is for members and patients. The purpose of this conference is to raise awareness of Psoriasis with speakers presenting and patients sharing their experiences of living with psoriasis. The conference ended with 'Question time' formed and closing remarks.
Year(s) Of Engagement Activity 2019
URL https://www.psoriasis-association.org.uk/awareness/50-for-50-project
 
Description Psoriasis Association 50th Anniversary Symposium - Prof Chris Griffiths Guest Oration: Psoriasis research in the UK: past present and future 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact As part of the Psoriasis Association's 50th Anniversary Symposium 'Psoriasis: translating innovation into personalised care" aimed at linking research outputs to clinical practice, Prof Chris Griffiths delivered a special Guest Oration: Psoriasis research in the UK: past present and future.
Year(s) Of Engagement Activity 2018
 
Description Psoriasis Association 50th Birthday Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Invited lecture delivered by Professor Nick Reynolds: Systems biology and computational modelling for psoriasis: future perspectives. Psoriasis: translating innovation into personalised care The Psoriasis
Year(s) Of Engagement Activity 2018
 
Description Psoriasis Association 50th Birthday symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Symposium entitled: 'Psoriasis: translating innovation into personalised care", at which both Prof Catherine Smith and Prof Jonathan Barker (King's College London) and Nick Reynolds (University of Newcastle) gave talks.

Impact: Generation of further interest in the outcomes of PSORT and contribution to the wider field
Year(s) Of Engagement Activity 2018
 
Description Psoriasis Association AGM 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact The Association is a partner in PSORT helping to inform the clinical studies based on questionnaires regarding treatment completed by patients / members of the Association, The talk was to inform patients and members on the progress of PSORT, to update on next steps and to thank the Association for its continued support. The talk was well received, generating questions and discussion.
Year(s) Of Engagement Activity 2017
 
Description Psoriasis Association AGM 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact The Association is a partners in PSORT helping to inform the clinical studies based on questionnaires regarding treatment completed by patients / members of the Association, The talk was to inform patients and members on the progress of PSORT, to update on next steps and to thank the Association for its continued support.

The talk was well received, generating questions and discussion,
Year(s) Of Engagement Activity 2016,2017
 
Description Psoriasis PPI 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact The PPI event was held in the evening of 07-NOV-2019. The meeting was used to discuss local psoriasis research opportunities and treatment options. The PPI event was also used to feedback current research project findings and updates to the attendees. The meeting was also an opportunity for attendees to ask questions of local clinicians and investigators and this was used to help develop future research and treatment strategies.
Year(s) Of Engagement Activity 2019
 
Description Psoriasis: Next Generation Healthcare - Let's Talk Psoriasis! Event for people living with psoriasis 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact A very engaging and interactive series of presentations and speaker/audience discussions on a range of topics including, advice on living well with psoriasis, treatment choices and current research into the condition.

Event chaired by Professor Chris Griffiths, Dermatologist , University of Manchester with talks from Helen McAteer, Chief Executive, Psoriasis Association UK, Dr Zenas Yiu, Dermatologist, Salford Royal NHS Foundation Trust, Dr Kerry Montgomery, Research consultant discussing "Mindfulness" - What is it and how might it help me? and Helen Hanrahan, Fashion Blogger and Patient Advocate.
Year(s) Of Engagement Activity 2018
 
Description Psoriasis: Next Generation Healthcare - Psoriasis Rapid Access Clinic Launch 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact This event saw the launch of a new Psoriasis Rapid Access Clinic (PRAC) in Salford, Manchester aimed at improving the speed of psoriasis treatment times.

It is intended that patients with psoriasis will be empowered to better manage their condition with the rapid access clinic designed to improve access to education and personalised treatment.

The Rapid Access Clinic will provide newly-diagnosed patients with a complete and specialist assessment of their psoriasis and education about how to best manage the disease.

The event was a launch and awareness raising exercise with interesting talks pertaining to The Greater Manchester (GM) Health and Social Care Partnership and how precision health fits into the GM agenda; the importance of psoriasis research from a patient's perspective and Personalised Medicine in Psoriasis.
Year(s) Of Engagement Activity 2018
URL http://www.srft.nhs.uk/media-centre/latest-news/news-archive/news-2018/psoriasis-clinic-launch/
 
Description Seminar on ESDR EADV Summer Research Workshop, Naples (Prof Nick Reynolds) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact 20 participants selected for 1 week intensive research workshop. Professor Nick Reynolds (Newcastle University - PSORT Consortium partner) presented on Transcriptomic analysis of psoriasis following UVB and biologic therapy and presented some unpublished data emanating from their on-going Rosetrees study.
Year(s) Of Engagement Activity 2018
 
Description Sharm Derma, Cairo 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Medical conference for Dermatologists consisting of speakers which sparked questions and discussion afterwards.
Year(s) Of Engagement Activity 2019
 
Description St John's DermAcademy Clinical Dermatology Care Course 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Spoke at the Clinical Dermatology Care Course study day Psoriasis on "What is psoriasis?", Learning outcomes: to describe the clinical features and natural history of psoriasis, to explain the underlying causes and modifiable risk factors of psoriasis, to describe sources of high quality information on the management approach to psoriasis
Year(s) Of Engagement Activity 2019
 
Description St John's Institute of Dermatology PPI event 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact Held bi-annually in May and October, members of the PSORT team and others gave talks about some of the latest findings in dermatology research including those from PSORT. They provided a forum in which patients could ask questions about the current work
Year(s) Of Engagement Activity 2018
 
Description St Johns Institute of Dermatology patient and public involvement events 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact Held at least bi-annually at Guy's Hospital. At such events, members of the St Johns Institute of Dermatology team and where relevant external researchers give talks about some of the latest findings in dermatology research, our current portfolio of studies and provide a forum in which patients can ask questions about the current work and any other particular concerns or feedback they have about research or the current service received for treatment. It is also used as a forum in which researchers can ask questions of patients about what kind of research activities they are willing to perform and what compensation they should receive for their time, if any, to provide valuable feedback which can be used to tailor research proposals and inform study amendments for existing studies to improve study design and engagement.

An example of a meeting can be found in the link below
Year(s) Of Engagement Activity 2015,2016,2017,2018,2019
URL https://www.guysandstthomas.nhs.uk/resources/our-services/dermatology/psoriasis-patient-and-public-i...
 
Description St Johns Institute of Dermatology, Guys hospital: psoriasis and eczema PPI event (summer) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact The Association is a partner in PSORT helping to inform the clinical studies based on questionnaires regarding treatment completed by patients / members of the Association. The talk was to inform patients and members on the progress of PSORT, to update on next steps and to thank the Association for its continued support. The talk was well received, generating questions and discussion.The most significant outcome/impact was the requests about (further) participation or involvement; patients better understood what we could, and what we were trying to achieve with their participation.
Year(s) Of Engagement Activity 2017
 
Description St Johns Institute of Dermatology, Guys hospital: psoriasis and eczema PPI event (winter) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact Members of the PSORT team and others gave talks about some of the latest findings in dermatology research, our current portfolio of studies and provided a forum in which patients could ask questions about the current work. Researchers were also able to ask patients some questions about what kind of research activities they would participate in, e.g. no. of biopsies. The most significant impact of this activity was the requests about (further) participation or involvement; patients better understood what we could and what we were trying to achieve with their participation.
Year(s) Of Engagement Activity 2017
 
Description THE TIMES: She knows why you really have that spot 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Expert commentary on treating psoriasis and how your mind affects your skin.
Year(s) Of Engagement Activity 2019
URL https://www.thetimes.co.uk/article/she-knows-why-you-really-have-that-spot-8sc9kxlkq
 
Description Therapeutic Drug Monitoring Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Symposium entitled: 'Contemporary use of therapeutic drug monitoring of biologics in chronic diseases:
From point of care to personalised medicine'. Prof Catherine Smith (King's College London) gave a talk on 'Personalized dosing of biologics in dermatology' to an audience including industry experts, clinicians and academic scientists from across disciplines in which biologics are prescribed

Impact - Generation of further interest in the outcomes of PSORT and contribution to the wider field
Year(s) Of Engagement Activity 2018
 
Description Workshop for Irish healthcare practitioners 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact A workshop designed to Engage, Reflect and Advance Irish HCPs on the current and future practices of Psoriasis.
The focus will be initially on treatment goals with the view to discussing ambitions for care to address evolving patient needs in Ireland.
This was a 30 min workshop followed by a Q/A session. Feedback suggested a deeper understanding of the current management of psoriasis in terms of treatment goals and the challenges faced by HCPs in achieving higher treatment targets.
Year(s) Of Engagement Activity 2019